相关ETF:医疗器械ETF（562600） 每日经济新闻 1月13日，A股市场整体震荡调整，医疗器械ETF（562600）逆势走强，收涨1.05%，实现四连阳。盘面 上，AI医疗应用方向延续强势，天智航上涨16.62%，迪安诊断上涨11.9%，贝瑞基因上涨9.97%，九强 生物上涨9.41%，春立医疗、凯普生物、华大基因等涨超6%。资金上，昨日医疗器械ETF（562600）成 交额达6614.53万元，交投活跃度显著提升。 消息面上，我国脑机接口产业开年迎来技术突破、资本加持、政策赋能三重共振。技术层面，国内多家 企业完成侵入式脑机接口临床试验，高位截瘫患者可通过意念操控智能设备，实现从"实验室演 示"到"生活实用"的跨越；资本层面，非侵入式领域企业强脑科技完成约20亿元融资，创下全球该领域 第二大融资纪录；政策层面，四川明确侵入式脑机接口医疗服务价格，多地已落地相关支付政策，国家 药监局公示两项脑机接口行业标准立项，为产业发展提供全方位制度保障。 作为"十五五"规划明确的未来产业，脑机接口千亿级产业生态雏形渐显，医疗器械ETF（562600）所跟 踪的中证全指医疗器械指数脑机接口占比达23.8%，在已上市E ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - Tongdahai, located in Chongqing, is a core service provider in the court informationization sector, focusing on judicial AI applications with over 2,000 courts using its products nationwide [1] - The company's intelligent document generation system improves judges' work efficiency by over 50%, while its intelligent case allocation system meets the smart management needs of courts [1] - As demand for judicial AI continues to grow, the company is expected to enhance its market coverage and commercialization capabilities, becoming a key beneficiary in the judicial AI sector [1] Group 2 - Tianlong Group, based in Shantou, Guangdong, operates in digital marketing and ink chemicals, with a strong focus on AI applications in digital marketing [2] - The company’s advertising optimization through AI technology has increased conversion rates by over 30% compared to traditional methods [2] - AI applications are driving the company's performance growth, leveraging its technical expertise and channel resources to meet advertisers' needs [2] Group 3 - Guangyun Technology, a leading player in the e-commerce SaaS sector based in Hangzhou, focuses on AI application development for e-commerce scenarios [3] - Its AI selection system provides precise product recommendations based on comprehensive e-commerce data analysis [3] - The company is expected to maintain its leading position in the e-commerce AI sector as demand for intelligent solutions increases [3] Group 4 - Zhangqu Technology, located in Beijing, is an established player in the mobile gaming industry, innovating AI applications in game development [4] - AI-generated content tools reduce development cycles by 20%-30% and costs by over 15% [4] - The company is positioned to leverage AI applications for intelligent transformation in the gaming business [4] Group 5 - Zhuoyi Information, based in Wuxi, Jiangsu, specializes in cloud computing infrastructure and AI computing power services [5] - The company optimizes AI computing power scheduling efficiency, supporting large model training and inference [5] - As demand for AI computing power continues to grow, the company is set to benefit significantly from its foundational role in AI application deployment [5] Group 6 - Dian Diagnostics, a leading third-party medical diagnostics company in Hangzhou, focuses on AI applications in the medical field [6] - Its AI diagnostic systems achieve over 95% accuracy in identifying cancer cells and enhance diagnostic efficiency [6] - The company is expected to expand its AI application scenarios in the medical sector, driving intelligent transformation in diagnostics [6] Group 7 - Zhidema, based in Beijing, operates a consumer content and shopping guide platform, integrating AI technology for consumer decision-making [7] - The platform's conversion rate is 40% higher than the industry average due to its AI recommendation system [7] - AI applications are crucial for enhancing user experience and monetization in the consumer sector [7] Group 8 - Yidian Tianxia, located in Xi'an, focuses on AI marketing applications for cross-border e-commerce and overseas enterprises [8] - The company’s AI creative platform generates multilingual advertising materials, adapting to various cultural contexts [8] - As demand for cross-border AI marketing grows, the company is positioned as a key bridge for enterprises entering AI applications [8] Group 9 - Weishidun, a digital transformation service provider, specializes in AI applications for the financial and government sectors [9] - Its intelligent risk control system effectively identifies financial risks, reducing bad debt rates [9] - The company is expected to expand its market share in financial and government AI solutions as demand increases [9] Group 10 - Xinlicheng, based in Zhengzhou, focuses on AI applications in grassroots medical services and health management [10] - The company’s AI-assisted diagnostic systems enhance the capabilities of grassroots doctors [10] - As the government promotes improvements in grassroots medical capabilities, the company is set to enhance service accessibility and quality through AI [10] Group 11 - Waifu Holdings, located in Shanghai, is a leader in human resources services, integrating AI technology into its applications [11] - The AI recruitment system improves hiring efficiency by over 60% [11] - The company is positioned to expand its AI applications in human resources, driving the sector's digital transformation [11] Group 12 - Zhonggong Education, based in Wuhu, is a leading vocational education company focusing on AI applications [12] - Its AI learning platform generates personalized study plans, enhancing learning efficiency [12] - The company is expected to solidify its leading position in vocational education through innovative AI applications [12] Group 13 - Zhizhen Technology, located in Beijing, focuses on AI applications in the telecommunications sector [13] - Its AI network operation system enhances network stability and reduces operational costs [13] - The company is set to expand its market share in telecommunications AI solutions as demand grows [13] Group 14 - Visual China, based in Chongqing, is a leader in visual content services, leveraging AI to transform content production and transaction [14] - The company’s AI content generation platform supports efficient visual content creation [14] - As demand for AI-generated visual content increases, the company is positioned to benefit significantly in this sector [14] Group 15 - Yiyuan Media, located in Beijing, is an integrated marketing service provider focusing on AI marketing applications [15] - The company’s AI marketing creative platform generates advertising materials quickly, adapting to short video marketing needs [15] - AI is a core technology driving innovation in the marketing sector, positioning the company as a leader in AI marketing [15] Group 16 - Shenguang Group, based in Guangzhou, is a leading advertising marketing company that integrates AI technology into its global marketing applications [16] - The company’s AI creative center generates multilingual advertising content, catering to overseas market needs [16] - As cross-border AI marketing demand grows, the company is expected to strengthen its position in the marketing industry [16]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流入合计2.74亿元，游资资金净流出合 计8537.29万元，散户资金净流出合计1.88亿元。成份股资金流向详情见下表： 证券之星消息，1月13日，生物经济（970038）指数报收于2312.84点，涨0.68%，成交478.37亿元，换 手率3.49%。当日该指数成份股中，上涨的有30家，迪安诊断以11.9%的涨幅领涨，下跌的有19家，美 好医疗以6.93%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： ...

每经AI快讯，迪安诊断发布公告称，2026年1月11日，迪安诊断接受国信证券组织的投资者调研，公司 副总裁、首席信息官吴维严等人参与接待，并回答了投资者提出的问题。 每经头条（nbdtoutiao）——"春节也要加班，抢在4月1日前交货"！有光伏企业在抢出口，也有企业很 纠结：白银等原材料成本激增，决策困难 （记者 王晓波） ...

迪安诊断(300244.SZ)接受机构调研时表示，AI将推动医疗健康应用快速发展，尤其在基层医疗与健康 管理场景。但复杂病症与循证医学领域的AI应用仍需高质量多模态数据支撑。患者端将受益于全生命 周期健康管理；在医生端，AI主要作为辅助工具，助力经验知识平民化。迪安通过"临床科研+基层赋 能"闭环推动产品落地。目前公司的AI相关业务尚处于起步阶段，相关业务收入占整体营业收入的比例 极小。 ...

| | 特定对象调研 分析师会议 √ □ | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会 □ □ | | | 新闻发布会 路演活动 □ □ | | 活动类别 | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位 | 国信证券组织的投资者 | | 时间 | 2026 年 1 月 11 日 | | 地点 | 进门财经电话会议 | | 上市公司接 | 副总裁、首席信息官 吴维严 | | | 副总裁、董事会秘书 陶钧 | | 待人员姓名 | 医策科技 王晓梅 CEO | | | 公司管理层对投资者提问的回复情况如下： | | | 1．AI 对医疗行业是否带来结构性重塑？ | | | 答：将推动医疗健康应用快速发展，尤其在基层医疗与健康 | | | 管理场景。但复杂病症与循证医学领域的 AI 应用仍需高质量多 | | | 模态数据支撑。患者端将受益于全生命周期健康管理；在医生端， | | | AI 主要作为辅助工具，助力经验知识平民化。迪安通过"临床科 | | 投资者关系 | 研+基层赋能"闭环推动产品落地。 | | 活动主要内 | 【风险提示：目前公司的 AI ...

证券之星消息，1月13日医疗服务板块较上一交易日上涨4.15%，诺思格领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301333 | 诺思格 | 76.48 | 20.01% | 5.52万 | | 3.97亿 | | 301257 | 電影斯 | 72.24 | 20.00% | 2.29万 | | 1.56亿 | | 301230 | 泓博医药 | 56.64 | 20.00% | 5.72万 | | 3.24亿 | | 301060 | 兰卫医学 | 13.28 | 19.96% | 1 35.21万 | | 4.41亿 | | 300404 | 博济医药 | 12.92 | 19.96% | 62.71万 | | 7.76亿 | | 300244 | 迪安诊断 | 29.16 | 11.90% | 151.60万 | | 46.46亿 | ...

在此背景下，医疗器械ETF（562600）成为布局医疗科技前沿的核心工具。该基金跟踪中证全指医疗器 械指数，成分股中脑机接口权重合计高达23.8%，为目前市场上同类ETF中暴露最纯、覆盖最广的产 品。同时，其医疗器械行业占比达89.2%，重仓股囊括迈瑞医疗、联影医疗、迪安诊断等行业龙头，精 准捕捉细分赛道爆发红利。 对于场外投资者，可通过华夏中证全指医疗器械ETF发起式联接A（021250）和C类份额（021251）低 门槛参与，灵活定投布局长期成长机遇。 1月13日，A股市场整体震荡调整，波动显著加大。医疗器械ETF（562600）走势较强，截至发稿，上涨 1.58%。盘面显示，医疗科技方向逆势领涨，AI赋能医疗应用场景持续升温，迪安诊断涨停，九强生物 上涨12.86%。 资金动向方面，医疗器械ETF（562600）持续获得增量资金抢筹，近五个交易日累计净流入达1.4亿 元，显示出投资者对医疗科技赛道的看好。截至发稿，该基金当日成交额已突破4000万元，交投活跃度 显著提升。 政策加持下，脑机接口、AI辅助诊断、智能影像设备等高技术壁垒领域或迎来发展黄金期。随着"十五 五"规划对生命健康与前沿技术融合发展的 ...

昨天联手大涨的商业航天和AI应用板块，今天上午，两者走势"分道扬镳"。 商业航天板块大幅波动，在早盘的前7分钟，板块持续下跌，中国卫通、航天发展、航天机电等多只人气股直线跌停。10:35之后，商业航天板块迎来修 复，临近上午收盘，板块拉升，跌幅收窄。 AI应用继续上涨，其中，"AI+制药""AI+医疗"方向走势最强。迪安诊断、中文在线、天龙集团等个股大涨。 此外，保险、油气开采、锂矿等板块上涨。截至上午收盘，上证指数下跌0.03%，深证成指下跌0.31%，创业板指下跌0.83%。 | 医药股大涨 | | --- | | 今天上午，医药股大涨，医疗服务、生物制品等板块涨幅居前。 | | 迪安诊断 | 31.27 | 19.99% | 157亿 | | --- | --- | --- | --- | | 融 300244 | | | | | 3天3板 最终涨停09:35 | | | | | 兰卫医学 | 13.28 | 19.96% | 47.8 Z | | 融 301060 | | | | | 首板涨停 最终涨停 09:55 | | | | | 博深失药 | 12.92 | 19.96% | 36.3 Z | ...